Shire PLC (SHP) Earns Conviction-Buy Rating from Goldman Sachs Group, Inc. (The)
Shire PLC (LON:SHP)‘s stock had its “conviction-buy” rating reaffirmed by research analysts at Goldman Sachs Group, Inc. (The) in a research report issued to clients and investors on Friday. They presently have a GBX 6,000 ($78.92) target price on the biopharmaceutical company’s stock. Goldman Sachs Group, Inc. (The)’s target price would suggest a potential upside of 62.23% from the stock’s current price.
Other equities research analysts have also recently issued research reports about the stock. Deutsche Bank AG reissued a “buy” rating and set a GBX 6,000 ($78.92) target price on shares of Shire PLC in a research report on Friday, August 4th. Jefferies Group LLC reissued a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 22nd. Citigroup Inc. reissued a “buy” rating and set a GBX 6,300 ($82.86) target price on shares of Shire PLC in a research report on Tuesday, August 22nd. Shore Capital reissued a “buy” rating on shares of Shire PLC in a research report on Tuesday, August 15th. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 6,000 ($78.92) target price on shares of Shire PLC in a research report on Wednesday, August 9th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Shire PLC currently has an average rating of “Buy” and an average price target of GBX 5,250 ($69.05).
Shares of Shire PLC (LON SHP) opened at GBX 3,698.50 ($48.65) on Friday. Shire PLC has a 52-week low of GBX 3,435.50 ($45.19) and a 52-week high of GBX 5,067 ($66.64).
In other Shire PLC news, insider Anne Minto acquired 190 shares of the business’s stock in a transaction dated Friday, September 29th. The shares were purchased at an average price of GBX 3,785 ($49.78) per share, for a total transaction of £7,191.50 ($9,458.77).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.